Sinotherapeutics Inc. A (688247 SHG) stock market data APIs
Sinotherapeutics Inc. A Financial Data Overview
Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality standard establishment, and regulatory dossier document preparation and submission. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sinotherapeutics Inc. A data using free add-ons & libraries
Get Sinotherapeutics Inc. A Fundamental Data
Sinotherapeutics Inc. A Fundamental data includes:
- Net Revenue: 509 M
- EBITDA: 135 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
